Skip to Content

Navidea Biopharmaceuticals Inc NAVB

Morningstar Rating
$0.00 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

NAVB is trading at a 591% premium.
Price
$0.00
Fair Value
$3.17
Uncertainty
Extreme
1-Star Price
$9.65
5-Star Price
$5.36
Economic Moat
Rzcf
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NAVB is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.000.15
Bid/Ask
$0.00 / $0.04
Market Cap
$100,084.39
Volume/Avg
270 / 45,578

Key Statistics

Price/Earnings (Normalized)
Price/Sales
90.91
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Navidea Biopharmaceuticals Inc is a biotechnology company specializied in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
15

Valuation

Metric
NAVB
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
90.91
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
NAVB
Quick Ratio
0.49
Current Ratio
0.56
Interest Coverage
Quick Ratio
NAVB

Profitability

Metric
NAVB
Return on Assets (Normalized)
−169.81%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
NAVB
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
ZllzlrrjmyCcfc$598.1 Bil
Vertex Pharmaceuticals Inc
VRTX
DwykzdmmVpbdrzr$126.0 Bil
Regeneron Pharmaceuticals Inc
REGN
KynjsvzPbtncqc$119.6 Bil
Moderna Inc
MRNA
VkbksgbTxn$47.5 Bil
Alnylam Pharmaceuticals Inc
ALNY
JvtbqfzkXpvchr$30.4 Bil
argenx SE ADR
ARGX
LbmpqwzcPjvr$27.4 Bil
BioNTech SE ADR
BNTX
ZylgrmjrPqr$20.8 Bil
Biomarin Pharmaceutical Inc
BMRN
SqzlvxlbPmqqcr$16.1 Bil
United Therapeutics Corp
UTHR
DpbrhyhpYyqjf$14.7 Bil
Incyte Corp
INCY
FdrssvhbPwwdy$12.9 Bil

Sponsor Center